Doctors support eteplirsen approval

A group of thirty-six doctors who specialize in Duchenne muscular dystrophy sent a letter to the Food and Drug Administration that urged approval of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) experimental treatment eteplirsen. Shares of the biopharmaceutical leaped $3.61 to $21.61.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.